Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on August 15, 2025

We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve

Simply Wall St.

a day ago

We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve

Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions

StockStory

a day ago

Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions

Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks

StockStory

a day ago

Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks

Argus Research

2 days ago

Technical Assessment: Bullish in the Intermediate-Term

MT Newswires

3 days ago

Market Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog

GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus

StockStory

3 days ago

GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus

Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir

Insider Monkey

3 days ago

Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir

MT Newswires

4 days ago

Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $136 From $132

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks

4 days ago

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

MT Newswires

4 days ago

Deutsche Bank Adjusts Gilead Sciences Price Target to $135 From $120, Maintains Buy Rating

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire

4 days ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Company News for Aug 11, 2025

Zacks

4 days ago

Company News for Aug 11, 2025

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

Barrons.com

4 days ago

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish

Insider Monkey

6 days ago

Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish

Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

6 days ago

Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations

Nasdaq posts record closing high with tech gains, rate cut optimism

Reuters Videos

6 days ago

Nasdaq posts record closing high with tech gains, rate cut optimism

S&P 500 Gains and Losses Today: Apple Stock Extends Its Rise; The Trade Desk Craters After Earnings

Investopedia

6 days ago

S&P 500 Gains and Losses Today: Apple Stock Extends Its Rise; The Trade Desk Craters After Earnings

MT Newswires

7 days ago

Equity Markets Close Higher After Earnings, Fed's Musalem Inflation, Labor Remarks

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More

Barrons.com

7 days ago

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More

Associated Press

7 days ago

How major US stock indexes fared Friday, 8/8/2025

MT Newswires

7 days ago

US Equity Markets Rise, Nasdaq Climbs to Record After Week Packed With Corporate Earnings

Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP

Investor's Business Daily

7 days ago

Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP

MT Newswires

7 days ago

Equity Markets Rise After Corporate Earnings; Fed's Musalem Sees Labor, Inflation Risks

Stock Market Today: Dow Rises, But Under Armour Plunges On This Warning (Live Coverage)

Investor's Business Daily

7 days ago

Stock Market Today: Dow Rises, But Under Armour Plunges On This Warning (Live Coverage)

MT Newswires

7 days ago

UBS Raises Price Target on Gilead Sciences to $112 From $108, Maintains Neutral Rating

MT Newswires

7 days ago

Assembly Biosciences Prices 5.6 Million Shares; Gilead to Buy 2.3 Million Shares in Private Offering

MT Newswires

7 days ago

JPMorgan Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Overweight Rating

MT Newswires

7 days ago

Baird Adjusts Price Target on Gilead Sciences to $108 From $100, Maintains Neutral Rating

MT Newswires

7 days ago

BMO Capital Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Outperform Rating

MT Newswires

7 days ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Neutral Rating

MT Newswires

7 days ago

TD Cowen Adjusts Price Target on Gilead Sciences to $115 From $110, Maintains Buy Rating

Stocks Gain Pre-Bell as Trump's Sweeping New Tariffs Take Effect; Investors Assess Apple's $600 Billion US Investment Plan

MT Newswires

8 days ago

Stocks Gain Pre-Bell as Trump's Sweeping New Tariffs Take Effect; Investors Assess Apple's $600 Billion US Investment Plan

PR Newswire

9 days ago

Compugen Reports Second Quarter 2025 Results

Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings

StockStory

9 days ago

Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

Investor's Business Daily

11 days ago

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

11 days ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks

11 days ago

Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?

Zacks

11 days ago

GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?

MT Newswires

11 days ago

Central Bank Outlook Lifts Wall Street Pre-Bell; Asia, Europe Up

Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors

GlobeNewswire

14 days ago

Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors

MT Newswires

14 days ago

Pharma Stocks Fall Pre-Bell After Trump's Letters to Companies Over Drug Pricing

Trump Talks Tough on Drug Prices but His Demands Have Softened

Barrons.com

14 days ago

Trump Talks Tough on Drug Prices but His Demands Have Softened

What Trump's Big Pharma CEO letters mean for drug pricing power

Yahoo Finance Video

15 days ago

What Trump's Big Pharma CEO letters mean for drug pricing power

Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs

The Wall Street Journal

15 days ago

Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs

Investing.com

15 days ago

Trump demands pharma CEOs lower drug prices within 60 days

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

15 days ago

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?

Are Wall Street Analysts Bullish on Gilead Sciences Stock?

Barchart

15 days ago

Are Wall Street Analysts Bullish on Gilead Sciences Stock?

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Zacks

16 days ago

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Infectious Disease Treatment Market Report 2025-2030 | Long-acting Injectables, Self-testing Kits, and Combination Therapies Fueling Growth

GlobeNewswire

16 days ago

Infectious Disease Treatment Market Report 2025-2030 | Long-acting Injectables, Self-testing Kits, and Combination Therapies Fueling Growth

Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL

Clinical Trials Arena

16 days ago

Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

GlobeNewswire

16 days ago

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

BMO says WSJ report on RFK potential headwind for Gilead

TipRanks

17 days ago

BMO says WSJ report on RFK potential headwind for Gilead

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Zacks

17 days ago

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Why Gilead Sciences Stock Slipped Today

Motley Fool

18 days ago

Why Gilead Sciences Stock Slipped Today

Investing.com

18 days ago

Biotech stocks dip as Trump administration mulls patent fee overhaul

Investing.com

18 days ago

Gilead Sciences stock falls amid reports of preventive health panel dismissal

Gilead wins positive European approval opinion for twice-yearly HIV injection

Pharmaceutical Technology

18 days ago

Gilead wins positive European approval opinion for twice-yearly HIV injection

HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore

PR Newswire

18 days ago

HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore

Citi Maintains a Buy Rating on Gilead Sciences (GILD)

Insider Monkey

18 days ago

Citi Maintains a Buy Rating on Gilead Sciences (GILD)

TD Cowen Remains Bullish on Gilead Sciences (GILD)

Insider Monkey

18 days ago

TD Cowen Remains Bullish on Gilead Sciences (GILD)

Why Gilead Sciences (GILD) Stock Is Up Today

StockStory

21 days ago

Why Gilead Sciences (GILD) Stock Is Up Today

Why Gilead Sciences Stock Just Popped

Motley Fool

21 days ago

Why Gilead Sciences Stock Just Popped

Solid Corporate Earnings Results Support Stocks

Barchart

21 days ago

Solid Corporate Earnings Results Support Stocks

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Zacks

21 days ago

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

MT Newswires

21 days ago

Needham Upgrades Gilead Sciences to Buy From Hold, Price Target is $133

MT Newswires

21 days ago

Gilead Sciences's HIV Prevention Drug Wins EU's Committee Backing

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

Business Wire

21 days ago

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Insider Monkey

21 days ago

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Business Wire

22 days ago

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva

GlobeNewswire

22 days ago

CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know

StockStory

23 days ago

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know

Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic

ACCESS Newswire

23 days ago

Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Barchart

23 days ago

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Zacks

23 days ago

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

MT Newswires

25 days ago

Truist Adjusts Price Target on Gilead Sciences to $108 From $97

MT Newswires

25 days ago

Truist Raises Price Target on Gilead Sciences to $108 From $97, Keeps Hold Rating

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector

Insider Monkey

a month ago

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

GlobeNewswire

a month ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

Zacks

a month ago

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

GlobeNewswire

a month ago

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player

GlobeNewswire

a month ago

Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks

a month ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

StockStory

a month ago

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Zacks

a month ago

Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $548,700, According to a Recent SEC Filing

MT Newswires

a month ago

Sector Update: Health Care Stocks Fall Late Afternoon

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention

Zacks

a month ago

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention

Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock

Insider Monkey

a month ago

Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations

Insider Monkey

a month ago

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations

MT Newswires

a month ago

Gilead Says Yeztugo Shows Broad Effectiveness, Tolerability for Diverse HIV Prevention

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

a month ago

WHO endorses Gilead’s Yeztugo for HIV prevention

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

Business Wire

a month ago

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

Barrons.com

a month ago

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom

MT Newswires

a month ago

Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom

MT Newswires

a month ago

Equity Markets Close Lower as Trade Tensions Escalate

MT Newswires

a month ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

a month ago

Equity Markets Lower After US Treasury Budget Surplus in June

Share on Social Networks: